Stemline
New York, US · 1 known investors
Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer. It is part of the Menarini Group, an international pharmaceutical and diagnostics company.
Founders & leadership
IB
Ivan Bergstein, M.D.Founder
Board
RB
Ronald BentsurBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$740K disclosed across 1 round · 2012
▶$740KraisedJan 2012 · 16 investors · PharmaceuticalsRule 506(b)
▶$740KraisedJan 2012 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ronald BentsurDirector
- Ivan Bergstein, M.D.Executive Officer, Director
- Amount sold
- $740K
- First sale
- Jan 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Stemline do?
- Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer. It is part of the Menarini Group, an international pharmaceutical and diagnostics company.
- Who founded Stemline?
- Stemline was founded by Ivan Bergstein, M.D..
- Who are Stemline's investors?
- Stemline's investors include Avoro Capital Advisors.
- How much funding has Stemline raised?
- Stemline has disclosed $740K raised across 1 round.
- Where is Stemline headquartered?
- Stemline is headquartered in New York, US.